Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

Quarterly Financial Data (Unaudited)

(In millions, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
2014	(a)		(b) (c)		(b)		(b)
Product revenues	$	1,742.8	$	2,056.3	$	2,117.3	$	2,287.0	$	8,203.4
Unconsolidated joint business revenues	$	296.9	$	303.3	$	290.7	$	304.5	$	1,195.4
Other revenues	$	90.1	$	61.9	$	103.4	$	49.2	$	304.5
Total revenues	$	2,129.8	$	2,421.5	$	2,511.4	$	2,640.7	$	9,703.3
Gross profit (1)	$	1,850.5	$	2,129.6	$	2,208.8	$	2,343.4	$	8,532.3
Net income	$	479.7	$	723.1	$	856.1	$	882.6	$	2,941.6
Net income attributable to Biogen Idec Inc.	$	480.0	$	714.5	$	856.9	$	883.5	$	2,934.8
Basic earnings per share attributable to Biogen Idec Inc.	$	2.03	$	3.02	$	3.63	$	3.75	$	12.42
Diluted earnings per share attributable to Biogen Idec Inc.	$	2.02	$	3.01	$	3.62	$	3.74	$	12.37

(In millions, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
2013	(d)		(e)		(e) (f)		(e)
Product revenues	$	1,095.8	$	1,385.9	$	1,453.6	$	1,607.1	$	5,542.3
Unconsolidated joint business revenues	$	264.6	$	288.8	$	303.2	$	269.4	$	1,126.0
Other revenues	$	54.7	$	48.8	$	71.0	$	89.4	$	263.9
Total revenues	$	1,415.1	$	1,723.5	$	1,827.8	$	1,965.9	$	6,932.2
Gross profit (1)	$	1,281.4	$	1,492.8	$	1,593.1	$	1,707.3	$	6,074.5
Net income	$	426.7	$	490.7	$	487.6	$	457.3	$	1,862.3
Net income attributable to Biogen Idec Inc.	$	426.7	$	490.7	$	487.6	$	457.3	$	1,862.3
Basic earnings per share attributable to Biogen Idec Inc.	$	1.80	$	2.07	$	2.06	$	1.94	$	7.86
Diluted earnings per share attributable to Biogen Idec Inc.	$	1.79	$	2.06	$	2.05	$	1.92	$	7.81

(1) Gross profit is calculated as total revenues minus cost of sales, excluding amortization of acquired intangible assets.

Full year amounts may not sum due to rounding.

(a) Net income and net income attributable to Biogen Idec Inc., for the first quarter of 2014, includes charges to research and development expense of $117.7 million recorded upon entering into the collaboration agreement with Eisai.

(b) Product revenues and total revenues for the second, third and fourth quarters of 2014 includes net revenues related to ALPROLIX, ELOCTATE and PLEGRIDY. Commercial sales of ALPROLIX commenced in the second quarter of 2014 and commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014.

(c) Product revenues and total revenues for the second quarter of 2014 includes the recognition of $53.5 million of revenue previously deferred in Italy relating to the pricing agreement with AIFA.

(d) Our share of revenues from unconsolidated joint business reflects a charge of $41.5 million for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.

(e) Product revenues and total revenues for the second, third and fourth quarters of 2013 includes 100% of net revenues related to sales of TYSABRI as a result of our acquisition of all remaining rights to TYSABRI from Elan on April 2, 2013 and net revenues related to sales of TECFIDERA, which was approved by the FDA in March 2013 and commenced commercial sales in April 2013.

(f) Net income and net income attributable to Biogen Idec Inc., for the third quarter of 2013, includes a charge to research and development expense of $75.0 million related to an upfront payment made in connection with our collaboration agreement entered into with Isis.